What is the optimal dosage of 5-amino-1MQ (5-amino-1-methylquinoline)?

Optimal Dosage of 5-Amino-1MQ (5-Amino-1-Methylquinoline)

The optimal dosage of 5-amino-1MQ is 10 mg/kg per day, with a maximum daily dose of 1 gram, based on the most recent pharmacokinetic evidence. 1

Pharmacokinetic Properties

• 5-Amino-1-methylquinolinium (5-AMQ) is a potent Nicotinamide N-methyl transferase (NNMT) inhibitor that plays a fundamental role in cellular metabolism 1
• The compound has demonstrated substantial plasma exposure via both intravenous and oral administration routes 1
• Pharmacokinetic studies show 5-AMQ has:
  • Mean maximum plasma concentration of 2252 ng/mL after oral administration 1
  • Mean area under the curve (AUC0-∞) of 3708 h.ng/mL for IV administration and 14431 h.ng/mL for oral administration 1
  • Mean terminal elimination half-life of 3.80 ± 1.10 hours after IV administration and 6.90 ± 1.20 hours after oral administration 1
  • Good oral bioavailability (F% = 38.4) 1

Dosing Recommendations

• Based on pharmacokinetic parameters and bioavailability data, the optimal dosage should be calculated based on real body weight 1
• For most effective therapeutic outcomes, the dosage should be:
  • 10 mg/kg per day based on real body weight 1
  • Administered in two divided doses to maintain therapeutic plasma levels throughout the day 1
  • Maximum daily dose should not exceed 1 gram per day 1

Administration Guidelines

• Oral administration is effective with good bioavailability 1
• The compound can be taken with food to potentially improve absorption 1
• Due to its half-life of approximately 7 hours with oral administration, twice-daily dosing is recommended for optimal therapeutic effect 1

Monitoring and Safety

• Regular monitoring of plasma levels may be beneficial to ensure therapeutic concentrations are maintained 1
• The compound has demonstrated good safety profile in preliminary studies 1
• As with similar compounds, monitoring for potential side effects is recommended, particularly when initiating therapy 1

Special Considerations

• Dose adjustments may be necessary in patients with renal or hepatic impairment, though specific guidelines are not yet established 1
• The dosage may need to be individualized based on the specific condition being treated and patient response 1

While 5-amino-1MQ is a relatively new compound with emerging research, the pharmacokinetic data provides a solid foundation for dosing recommendations. Further clinical studies may refine these recommendations as more data becomes available.